Executive Chairman & Co-Founder, Allogene Therapeutics Inc.

Belldegrun, an Israeli-born physician who still teaches urology at UCLA, founded cancer biopharmaceutical company Kite Pharma, which was acquired in 2017 for about $12 billion. He then co-founded Bellco Capital, which he also chairs. Belldegrun has used Bellco to fund and build several biotech companies, including Cougar Biotechnology, Agensys and South San Francisco-based Allogene Therapeutics. Belldegrun is also chair of New York-based venture capital firm Two River Group Holdings, as well as Israel-based UroGen Pharma, which is developing therapies for urinary tract cancers. In addition, he co-founded Vida Ventures, a life science venture capital firm with a portfolio of 29 companies and $1.7 billion in assets under management.

YEARS ON THE LA500: 7